Search Results for: CD40

Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
MAL mal, T cell differentiation protein (MAL blood group)
MAP3K8 mitogen-activated protein kinase kinase kinase 8
  • CD28 dependent PI3K/Akt signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
MIP major intrinsic protein of lens fiber
  • Passive transport by Aquaporins
  • B-nonylglucoside
MS4A1 membrane spanning 4-domains A1
  • Rituximab
  • Ibritumomab tiuxetan
  • Tositumomab
  • Ofatumumab
  • Obinutuzumab
  • Technetium Tc-99m nofetumomab merpentan
  • Ublituximab
  • Ocrelizumab
  • Mosunetuzumab
  • Odronextamab
NCOA6 nuclear receptor coactivator 6
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Cytoprotection by HMOX1
  • Heme signaling
  • Formation of WDR5-containing histone-modifying complexes
  • Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
NSMAF neutral sphingomyelinase activation associated factor
  • TNFR1-mediated ceramide production
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Signaling by ALK
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • RHOF GTPase cycle
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Signaling by LTK in cancer
  • Signaling by LTK
  • Co-stimulation by ICOS
  • SF1126
  • Enzastaurin
  • Wortmannin
PLP1 proteolipid protein 1
  • Hypomyelinating leukodystrophy (HLD); Pelizaeus-Merzbacher disease (PMD)
  • Hereditary spastic paraplegia (SPG)
RIPK2 receptor interacting serine/threonine kinase 2
  • NOD1/2 Signaling Pathway
  • NOD1/2 Signaling Pathway
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Fostamatinib
SLC30A2 solute carrier family 30 member 2
  • Zinc efflux and compartmentalization by the SLC30 family
SLC30A3 solute carrier family 30 member 3
  • Zinc efflux and compartmentalization by the SLC30 family
SLC39A13 solute carrier family 39 member 13
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
SLC61A1 solute carrier family 61 member 1
SLC7A1 solute carrier family 7 member 1
  • Amino acid transport across the plasma membrane
  • Lysine
  • Arginine
  • Ornithine
TANK TRAF family member associated NFKB activator
  • TICAM1-dependent activation of IRF3/IRF7
  • TRAF6 mediated IRF7 activation
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
  • Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
TDP2 tyrosyl-DNA phosphodiesterase 2
  • Nonhomologous End-Joining (NHEJ)
TLCD1 TLC domain containing 1
TMEM107 transmembrane protein 107
TMEM128 transmembrane protein 128

Page 2 out of 3 pages